Literature DB >> 10626190

Effects of nafamostat mesilate, a synthetic protease inhibitor, on immunity and coagulation after hepatic resection.

H Inagaki1, T Nonami, T Kurokawa, Y Takeuchi, N Okuda, A Nakao, J Sakamoto.   

Abstract

BACKGROUND/AIMS: Effects of nafamostat mesilate (NM), a serine protease inhibitor, on both coagulation-fibrinolysis activity and post-operative changes in immune responsiveness were investigated in a clinical study of 20 patients who underwent an extensive hepatic resection.
METHODOLOGY: The patients were randomly allocated into 2 groups of 10 patients each: The NM group was administered nafamostat mesilate (2 mg/kg/day) during and after the operation for 7 days. The control group received standard post-operative intensive therapies except NM.
RESULTS: The post-operative increase in coagulation in the control group was significantly suppressed in the NM-treated group on post-operative day (POD) 7. Natural killer (NK) activity, which was impaired after the operation, was recovered in the NM group on POD 7 and was significantly higher than in the control group. Helper/suppressor ratios of T lymphocytes were significantly increased post-operatively by the administration of NM.
CONCLUSIONS: These results demonstrate that NM controls the enhanced coagulation which occur in patients with extensive hepatic resection. It is also suggested that NM promptly restores the impaired immune responsiveness and decreases the risk of post-operative complications, as well as the risk of recurrence in patients with hepatic tumors.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10626190

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  5 in total

Review 1.  Pharmacological interventions for ischaemia reperfusion injury in liver resection surgery performed under vascular control.

Authors:  Mahmoud Abu-Amara; Kurinchi Selvan Gurusamy; George Glantzounis; Barry Fuller; Brian R Davidson
Journal:  Cochrane Database Syst Rev       Date:  2009-10-07

Review 2.  Systematic review of randomized controlled trials of pharmacological interventions to reduce ischaemia-reperfusion injury in elective liver resection with vascular occlusion.

Authors:  Mahmoud Abu-Amara; Kurinchi Gurusamy; Satoshi Hori; George Glantzounis; Barry Fuller; Brian R Davidson
Journal:  HPB (Oxford)       Date:  2010-02       Impact factor: 3.647

3.  Protective effects of nafamostat mesilate on liver injury induced by lipopolysaccharide in rats: possible involvement of CD14 and TLR-4 downregulation on Kupffer cells.

Authors:  Hideaki Miyaso; Yoshinori Morimoto; Michitaka Ozaki; Sanae Haga; Susumu Shinoura; Yasuhiro Choda; Hiroshi Murata; Goutaro Katsuno; Kamul Huda; Hideo Takahashi; Noriaki Tanaka; Hiromi Iwagaki
Journal:  Dig Dis Sci       Date:  2006-10-28       Impact factor: 3.199

Review 4.  Visceral hypersensitivity in inflammatory bowel diseases and irritable bowel syndrome: The role of proteases.

Authors:  Hannah Ceuleers; Hanne Van Spaendonk; Nikita Hanning; Jelena Heirbaut; Anne-Marie Lambeir; Jurgen Joossens; Koen Augustyns; Joris G De Man; Ingrid De Meester; Benedicte Y De Winter
Journal:  World J Gastroenterol       Date:  2016-12-21       Impact factor: 5.742

Review 5.  Be on Target: Strategies of Targeting Alternative and Lectin Pathway Components in Complement-Mediated Diseases.

Authors:  József Dobó; Andrea Kocsis; Péter Gál
Journal:  Front Immunol       Date:  2018-08-08       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.